Figure 2.
Development of an integrated model for LFS after transplantation. (A) The study workflow used to develop a prognostic model that included both genetic and nongenetic factors in the full cohort of 295 individuals. We additionally assessed whether the presence or absence of mutations at remission further refined the baseline mode in the 192 individuals with available remission samples. (B) LFS of individuals in the low (n = 35; green), intermediate (n = 113; blue), high (n = 71; orange), and very high (n = 77; red) risk groups. Cumulative incidence of relapse for the same groups (C), and the incidence of NRM (D). See supplemental Tables 8 to 10 for variables defining low, intermediate, high, and very high risk groups.

Development of an integrated model for LFS after transplantation. (A) The study workflow used to develop a prognostic model that included both genetic and nongenetic factors in the full cohort of 295 individuals. We additionally assessed whether the presence or absence of mutations at remission further refined the baseline mode in the 192 individuals with available remission samples. (B) LFS of individuals in the low (n = 35; green), intermediate (n = 113; blue), high (n = 71; orange), and very high (n = 77; red) risk groups. Cumulative incidence of relapse for the same groups (C), and the incidence of NRM (D). See supplemental Tables 8 to 10 for variables defining low, intermediate, high, and very high risk groups.

Close Modal

or Create an Account

Close Modal
Close Modal